View Older Stories View More Recent Stories
-
Galera and Obsidian merge in $350 million all-stock deal
-
Obsidian Therapeutics and Galera Therapeutics announce merger with $350M funding
-
American Integrity Insurance names Brian Foley as CFO
-
Ovid Therapeutics prices $60 million private placement for drug development
-
Korro Bio raises $85 million in oversubscribed private placement
-
Relmada Therapeutics raises $160 million in oversubscribed private placement
-
Sensei Biotherapeutics acquires Faeth Therapeutics for $200 million
-
Form SCHEDULE 13G Minerva Neurosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Contineum Therapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
LB Pharmaceuticals raises $100 million in private placement
-
Adlai Nortye raises $140 million in private placement financing
-
Crescent Biopharma raises $185 million, partners with Kelun-Biotech
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Spirit AeroSystems Holdi Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lottery.com Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Arcturus Therapeutics Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Lottery.com Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Camping World Holdings, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Avalo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Opus Genetics advances LCA5 gene therapy toward pivotal trial after FDA meeting
-
Opus Genetics raises $23 million in registered direct offering
-
Tango Therapeutics raises $225 million in stock offering
-
Expedia Group names Rob Bevegni as VP of investor relations
-
Minerva Neurosciences secures up to $200 million for schizophrenia drug trial
-
Lexeo Therapeutics closes $153.8 million public offering and private placement
-
Lexeo Therapeutics prices $135 million public offering at $8 per share
-
Lexeo Therapeutics launches stock offering and private placement
-
Ovid Therapeutics raises up to $175 million in private placement
-
CAMP4 raises up to $100 million for SYNGAP1 disorder treatment
-
CAMP4 raises up to $100 million for SYNGAP1 disorder treatment
-
iBio closes $50 million public offering led by Balyasny
-
Form SCHEDULE 13G/A Shapeways Holdings, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Camping World Holdings, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Spirit AeroSystems Holdi Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
F.N.B. Corp's (FNB) First National Bank names Chris Chan as CSO
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Hudson Pacific Propertie Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Shapeways Holdings, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

